Bionano Genomics, Inc. (NASDAQ:BNGO - Get Rating) - Equities research analysts at Oppenheimer decreased their Q3 2022 earnings per share (EPS) estimates for shares of Bionano Genomics in a note issued to investors on Monday, August 8th. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings per share of ($0.12) for the quarter, down from their previous forecast of ($0.10). Oppenheimer has a "Outperform" rating and a $12.00 price target on the stock. The consensus estimate for Bionano Genomics' current full-year earnings is ($0.37) per share. Oppenheimer also issued estimates for Bionano Genomics' Q4 2022 earnings at ($0.12) EPS and FY2022 earnings at ($0.45) EPS.
Bionano Genomics Price Performance
Shares of NASDAQ:BNGO opened at $3.00 on Thursday. The company has a quick ratio of 12.12, a current ratio of 7.75 and a debt-to-equity ratio of 0.01. Bionano Genomics has a 12-month low of $1.16 and a 12-month high of $6.28. The business has a fifty day simple moving average of $1.71 and a 200 day simple moving average of $1.89.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Mackenzie Financial Corp raised its position in Bionano Genomics by 24.1% during the 2nd quarter. Mackenzie Financial Corp now owns 20,760 shares of the company's stock worth $29,000 after purchasing an additional 4,037 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Bionano Genomics during the 2nd quarter worth about $27,000. Washington Trust Bank grew its holdings in Bionano Genomics by 49.3% during the 2nd quarter. Washington Trust Bank now owns 20,900 shares of the company's stock worth $29,000 after acquiring an additional 6,900 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Bionano Genomics by 45.7% during the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,519,630 shares of the company's stock worth $2,097,000 after acquiring an additional 476,405 shares during the period. Finally, Capital Wealth Alliance LLC acquired a new stake in Bionano Genomics during the 2nd quarter worth about $35,000. 26.35% of the stock is owned by institutional investors.
About Bionano Genomics
Bionano Genomics, Inc provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Bionano Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bionano Genomics wasn't on the list.
While Bionano Genomics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here